Good morning and welcome to the Devyser Q1 2026 Earnings Call. My name is Jan Wahlström. I'm the CEO of Devyser and would like to thank you, everyone for joining our call today. On the call today, we have in addition to myself, also our CFO, Sabina Berlin. I will start with a short summary of highlights from the quarter before handing over to Sabina for a more detailed review of our financial results for January to March.
And then we'll go through an update on our recent commercial activities.
The first quarter posted a positive EBIT for the fourth consecutive quarter. As you know, we started the journey in the beginning of last year, focusing the company towards profitable growth. It's been a successful journey, and we're happy to deliver strong growth and positive EBIT.
In the first quarter of the year, we continued to grow faster than the market.
We grew 24.4% in local currency. We received quite a few orders from Thermo Fisher Scientific in this quarter, a step towards a more stable order pattern.
We're also very pleased with the gross margin of 82%. It's better than full year 2025, and we will continue to work on improving cost of goods sold. EBIT came in at a positive 2.6 MSEK compared to last year's negative 14.8 MSEK in the first quarter. So we're growing faster than the market with a clear focus on profitable growth.
In the first quarter, we signed the agreement to acquire CyberGene, a Swedish company with products in similar areas as Devyser, giving us a stronger commercial position in several markets. CyberGene is a Stockholm-based diagnostic company and has operated in the same market as Devyser for many years, providing Devyser with in-depth knowledge of CyberGene products and customers. The acquisition was completed on April 1st and we have already integrated the company in our daily operations. CyberGene has demonstrated steady growth, driven by a strong product offering and consistent market expansion, and will contribute positively to Devyser's gross profit and gross margin.
As presented earlier in the year, in Q1, we also signed a significant agreement with Illumina, giving us the opportunity to do reagent rental on the European market. As we spoke about in the last quarter, we continue the ongoing MolDx application for a post-transplant kidney test as a service in the US. Since last quarter, we have gathered more clinical data and we are now analyzing the clinical samples. After that, we will send in a renewed application and hopefully we can have an approved product before the end of the year.
At the same time, we continue to work on our FDA project in transplantation, and we've had very positive development here.
We have all the six sites up and running, and we gather patients at a good pace and will continue to do so. We need 2026 and 2027 to be able to file in 2028 if everything develops in a positive way.
With that, I would like to hand over to Sabina to share more details on our financial results for Q1 2026.